Overview
- Total revenue rose about 83% year over year, with organic growth around 30% excluding Ambry.
- Diagnostics generated approximately $955 million, up about 111% on oncology testing volume growth near 26% and hereditary testing growth around 29%.
- Data and Applications produced roughly $316 million, up about 31%, driven by an estimated 38% increase in Insights data licensing.
- The company closed more than 70 data agreements with major drugmakers, pushing total contract value above $1.1 billion and delivering net revenue retention near 126%.
- Shares traded higher premarket on the news, while analysts maintain a Moderate Buy outlook with a median price target in the mid-$80s and management highlighting AI as a cross‑product catalyst.